Lisa Ricciardi Biography and Net Worth

Ms. Ricciardi joined Cognition Therapeutics in March 2019 as a member of the Board of Directors. She was appointed CEO in 2020 and led the company through its initial public offering. Her career experience includes drug development and commercialization, healthcare services and genomics. She has a proven track record launching large-market therapeutics as well as negotiating financial and business development agreements, from small to multi-billion-dollar deals.

Prior to her appointment as Cognition CEO, Ms. Ricciardi provided strategic counsel to biotech firms who were in the process of raising money. As senior vice president of business development at Foundation Medicine, she negotiated large-scale deals, such as the $1.03 billion transformational agreement with Roche and the acquisition of Medco by Express Scripts in 2011. At Pfizer Ms. Ricciardi was instrumental in launching major products including Norvasc, Zithromax, and Trovan, and later las SVP, led multiple global licensing efforts concentrating on international research and development and commercial partnerships.

Ms Ricciardi has served as a public company Director for public, private, US, International, precommercial and commercial Boards in the life science industry. Ms. Ricciardi earned a Bachelor of Arts cum laude in English and religion from Wesleyan University and a Master of Business Administration from the University of Chicago Booth School of Management.

What is Lisa Ricciardi's net worth?: The estimated net worth of Lisa Ricciardi is at least $1.78 million as of April 16th, 2026. Ricciardi owns 1,715,851 shares of Cognition Therapeutics stock worth more than $1,775,906 as of September 15th. This net worth approximation does not reflect any other assets that Ricciardi may own. Learn More about Lisa Ricciardi's net worth.
How do I contact Lisa Ricciardi?: The corporate mailing address for Ricciardi and other Cognition Therapeutics executives is , , . Cognition Therapeutics can also be reached via phone at 412-481-2210 and via email at [email protected]. Learn More on Lisa Ricciardi's contact information.
Has Lisa Ricciardi been buying or selling shares of Cognition Therapeutics?: Lisa Ricciardi has not been actively trading shares of Cognition Therapeutics during the last quarter. Most recently, on Thursday, April 16th, Lisa Ricciardi bought 9,175 shares of Cognition Therapeutics stock. The stock was acquired at an average cost of $1.10 per share, with a total value of $10,092.50. Following the completion of the transaction, the chief executive officer now directly owns 1,715,851 shares of the company's stock, valued at $1,887,436.10. Learn More on Lisa Ricciardi's trading history.
Who are Cognition Therapeutics' active insiders?: Cognition Therapeutics' insider roster includes John Doyle (CFO), Lisa Ricciardi (CEO), and Peggy Wallace (Director). Learn More on Cognition Therapeutics' active insiders.
Are insiders buying or selling shares of Cognition Therapeutics?: During the last year, Cognition Therapeutics insiders bought shares 2 times. They purchased a total of 19,175 shares worth more than $21,392.50. The most recent insider tranaction occured on April, 16th when CFO John Brendan Doyle bought 10,000 shares worth more than $11,300.00. Insiders at Cognition Therapeutics own 11.1% of the company. Learn More about insider trades at Cognition Therapeutics.
Information on this page was last updated on 4/16/2026.

Lisa Ricciardi Insider Trading History at Cognition Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/16/2026	Buy	9,175	$1.10	$10,092.50	1,715,851
3/14/2024	Buy	5,700	$1.75	$9,975.00	291,345
11/15/2022	Buy	12,000	$1.30	$15,600.00	24,500

Lisa Ricciardi Buying and Selling Activity at Cognition Therapeutics

Cognition Therapeutics Company Overview

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

Today's Range

Now: $1.04

$0.98

$1.04

50 Day Range

MA: $1.00

$0.89

$1.13

2 Week Range

Now: $1.04

$0.55

$2.05

Volume

430,270 shs

Average Volume

1,085,547 shs

Market Capitalization

$98.90 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.79